ArticleFrontiers in medicine2025
Epidemiological analysis and temporal trends of interstitial lung diseases in global, Chinese, and Belt and Road Initiative countries: 1990-2021.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to comprehensively evaluate the historical, current, and projected burden of interstitial lung diseases (ILD) across global populations, China, and the Belt and Road Initiative (BRI) countries. Additionally, exploring cross-national inequalities across socio-demographic index (SDI). Methods: From the 2021 Global Burden of Disease (GBD) database, we selected data on interstitial lung diseases (ILD) for global populations, China, and BRI countries. We analyzed the changes in the burden of ILDs according to year, sex, location, age, and SDI, and used the estimated annual percentage change (EAPC) to estimate the trends of the disease burden. Time trends were evaluated using Joinpoint analysis, while health disparities were assessed with the inequality slope index and concentration index. Additionally, the autoregressive integrated moving average (ARIMA) model was employed to forecast the future trends. Results: From 1990 to 2021, the global age-standardized incidence rate (ASIR) of interstitial lung diseases and sarcoidosis (ILD) increased from 3.77 per 100,000 (95% UI: 3.27, 4.28) to 4.55 per 100,000 (95% UI: 4.06, 5.04), with an EAPC of 0.73 (95% CI: 0.63, 0.82). Both the age-standardized mortality rate (ASMR) and the age-standardized disability-adjusted life year (DALY) rate (ASDR) also showed an increase. In 2021, China's ASIR was 2.32 per 100,000 (95% UI: 2.03, 2.65), ASMR was 0.39 per 100,000 (95% UI: 0.24, 0.53), and ASDR was 10.82 per 100,000 (95% UI: 7.70, 13.97). When it comes to rankings among BRI countries, China ranked 49.36% for ASIR, 17.95% for ASMR, and 17.31% for ASDR, from lowest to highest. Countries with higher SDI along the BRI countries had a faster annual average growth rate in ILD incidence, and the inequality in ILD between high SDI and low SDI countries was gradually increasing, albeit to a smaller extent. Predicting the trend of ASDR by 2031, it showed a global downward trend, while it showed an upward trend in Chinese. Conclusion: The ILD burden of BRI countries varies by region, gender, and time factors, and the unbalanced development of their regions exacerbates the imbalance of burden. Therefore, it is necessary to pay attention to and strengthen cooperation in the health field of BRI countries and promote the rational allocation of medical resources to help realize the construction of a community of human destiny.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.